Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series: World’s leading Event Organizer
As per available reports about 12 relevant journals, 8 Conferences, 70 workshops are presently dedicated exclusively to clinical transplantation about 455 articles are being published on clinical transplantation.
Clinical Transplantation is primarily designed as a guide of communication for all those involved in the care of people who require or have had organ or tissue transplants, including: kidney, intestine, liver, pancreas, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide
Scope and Importance:
Interest is focused not only on the complete spectrum of present transplant operations, but also those that are experimental or may become possible in future.
- immunology and immunosuppression
- patient preparation
- social, ethical and psychological issues
- complications, short- and long-term results
- artificial organs
- preservation and storage of organ and tissue
The emergence of transplantation has seen the development of gradually more potent immunosuppressive agents, increasingly better methods of tissue and organ preservation, refinements in histocompatibility matching, and various innovations in surgical techniques. Such efforts in combination ultimately made it potential to successfully engraft all of the organs and bone marrow cells in humans. At a more fundamental level, however, the transplantation endeavor hinged on two seminal turning points. The first was the acknowledgment by Billingham, Brent, and Medawar in 1953 that it was possible to induce chimerism-associated neonatal tolerance purposely. This discovery escalated over the next 15 years to the first successful bone marrow transplantations in humans in 1968. The second turning point was the demonstration all through the early 1960s that canine and human organ allografts could self-induce tolerance with the aid of immunosuppression. By the end of 1962, however, it had been wrongly concluded that turning points one and two involved different immune mechanisms. The error was not corrected until well into the 1990s. In this historical account, the vast literature that sprang up during the intervening 30 years has been summarized. Although admirably documenting empiric progress in clinical transplantation, its failure to explain organ allograft acceptance predestined organ recipients to lifetime immunosuppression and precluded fundamental changes in the treatment policies. After it was discovered in 1992 that long-surviving organ transplant recipients had persistent microchimerism, it was promising to see the mechanistic commonality of organ and bone marrow transplantation. A clarifying central principle of immunology could then be synthesized with which to guide efforts to induce tolerance systematically to human tissues and perhaps ultimately to xenografts.
The global transplant diagnostics market is poised to grow at a CAGR of 6.5% during 2014-2019, and is expected to reach a value of $645.0 Million in 2019. A number of factors such as growing geriatric population, coupled with an increasing population base for chronic disease patients, technological advancement in the field of HLA typing, rising number of solid organ, soft tissue, and stem cell-based transplantation procedures across the world, and increased public-private investments to develop innovative HLA testing products are fuelling the growth of the global market. However, high cost of PCR and NGS instruments and limited medical reimbursement available for transplantation procedures are some of the key factors negatively affecting the market growth.
The emerging markets including China, India, Brazil, and Mexico have become attractive destinations for companies engaged in the development and distribution of transplant diagnostic products. A number of factors such as growing preference from serological assay method to genome-based HLA profiling and increasing market penetration of transplant diagnostics product manufacturers across developing countries are offering high growth opportunities for the players’ active in this market.
Relevant Association and Society:
Company list :
1. Abbott Laboratories Inc. (U.S.),
2. Bio-Rad Laboratories Inc. (U.S.),
3. F. Hoffmann-La Roche, Ltd. (Switzerland),
4. Illumina, Inc. (U.S.),
5. Immucor, Inc. (U.S.),
6. Linkage Biosciences (U.S.),
7. Olerup Ssp Ab (Norway),
8. Qiagen N.V. (Netherlands)
9. Sigma- Aldrich (U.S.)
This page will be updated regularly.
This page was last updated on 12th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising